Trial Profile
Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Benmelstobart (Primary) ; Catequentinib (Primary)
- Indications Advanced breast cancer; Cervical cancer; Colorectal cancer; Malignant thymoma; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 21 Sep 2020 Status changed to active, no longer recruiting as per results presented at the 45th European Society for Medical Oncology Congress
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress
- 31 May 2020 Results (n=22) assessing safety and efficacy of TQ-B2450 plus anlotinib in advanced solid tumors, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.